Regenerx Biopharm In
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.013
- Today's High:
- $0.0178
- Open Price:
- $0.016
- 52W Low:
- $0.01
- 52W High:
- $3
- Prev. Close:
- $0.02
- Volume:
- 83686
Company Statistics
- Market Cap.:
- $2.40 million
- Book Value:
- -0.026
- Revenue TTM:
- $76760
- Operating Margin TTM:
- -1775.75%
- Gross Profit TTM:
- $70123
- Profit Margin:
- 0%
- Return on Assets TTM:
- -148.5%
- Return on Equity TTM:
- 0%
Company Profile
Regenerx Biopharm In had its IPO on 1986-12-23 under the ticker symbol RGRX.
The company operates in the Healthcare sector and Biotechnology industry. Regenerx Biopharm In has a staff strength of 2 employees.
Stock update
Shares of Regenerx Biopharm In opened at $0.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.02, and closed at $0.02.
This is a -23% slip from the previous day's closing price.
A total volume of 83,686 shares were traded at the close of the day’s session.
In the last one week, shares of Regenerx Biopharm In have slipped by -23%.
Regenerx Biopharm In's Key Ratios
Regenerx Biopharm In has a market cap of $2.40 million, indicating a price to book ratio of 0 and a price to sales ratio of 261.8127.
In the last 12-months Regenerx Biopharm In’s revenue was $76760 with a gross profit of $70123 and an EBITDA of $-1293125. The EBITDA ratio measures Regenerx Biopharm In's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Regenerx Biopharm In’s operating margin was -1775.75% while its return on assets stood at -148.5% with a return of equity of 0%.
In Q1, Regenerx Biopharm In’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Regenerx Biopharm In’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regenerx Biopharm In’s profitability.
Regenerx Biopharm In stock is trading at a EV to sales ratio of 298.4489 and a EV to EBITDA ratio of -15.686. Its price to sales ratio in the trailing 12-months stood at 261.8127.
Regenerx Biopharm In stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $186810.00
- Total Liabilities
- $1.80 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Regenerx Biopharm In ended 2024 with $186810.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $186810.00 while shareholder equity stood at $-3744335.00.
Regenerx Biopharm In ended 2024 with $0 in deferred long-term liabilities, $1.80 million in other current liabilities, in common stock, $-112602368.00 in retained earnings and $0 in goodwill. Its cash balance stood at $101557.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $262015.00.
Regenerx Biopharm In’s total current assets stands at $123257.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $38693.00 and inventory worth $0.
In 2024, Regenerx Biopharm In's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Regenerx Biopharm In paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.02
- 52-Week High
- $3
- 52-Week Low
- $0.01
- Analyst Target Price
- $
Regenerx Biopharm In stock is currently trading at $0.02 per share. It touched a 52-week high of $3 and a 52-week low of $3. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.09 and 200-day moving average was $0.1 The short ratio stood at 0.15 indicating a short percent outstanding of 0%.
Around 4413.7% of the company’s stock are held by insiders while 0.7% are held by institutions.
Frequently Asked Questions About Regenerx Biopharm In
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.